Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Sponsor
Hannover Medical School
Study ID
NCT06391450
Phase
PHASE4
Status
Active Not Recruiting

Conditions

  • Autosomal Dominant Polycystic Kidney

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.

Key Dates

Start date
Jun 14, 2024
Status verified
Nov 2025
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
44 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin 10 milligram (MG)
  • Placebo Comparator: Placebo

Primary Outcome Measure

Total kidney volume (TKV) [ Time Frame: 18 months ]

Related Studies